30.03.2025, 3094 Zeichen

Porr: Construction group Porr grew again in 2024: The order backlog increased by 1.1% to EUR 8.5 bn. PORR acquired a total of EUR 6,846m in new orders – an increase of 0.2% despite the high comparative value from the previous year. These include the construction of a large data centre worth almost EUR 200m and a production plant for a pharmaceutical company worth around EUR 100m, both in Germany. In the fourth quarter, PORR was awarded the contract for replacing the Lueg Bridge in Austria, one of several orders in the civil engineering sector. In the order backlog, the high level of the previous year was thereby exceeded by 1.1%, bringing the total to EUR 8,543m. Thanks to significant efficiency improvements and absolute savings in the cost of materials and other related services, EBITDA increased by 7.1% to EUR 368.8m – despite the significant increase in staff expense. EBIT rose even more sharply by 12.9% to EUR 158.4m. PORR CEO Karl-Heinz Strauss said: “The figures speak for themselves: In 2024 we achieved excellent results with PORR in a mixed economic environment. This shows that we have the right positioning on our home markets and that we are consistently driving forward our intelligent growth thanks to the wide range of services that we offer”. While EBIT rose by 12.9% to EUR 158.4m, earnings per share also improved to EUR 2.32. 
Porr: weekly performance: -5.27%

Marinomed: Marinomed Biotech AG has realigned its finances after a successful restructuring and is optimistic about the future. After receiving a first payment of EUR 5 million, further financial stability should be ensured by the milestone payments and the ongoing transition service agreement following the sale of the Carragelose business to Unither Pharmaceuticals. This allows Marinomed to focus operationally on the Marinosolv technology, which is used to enhance the solubility of hydrophobic compounds. A solid financial basis is the foundation for the next operational successes. Following the completion of the restructuring process and the sale of the Carragelose business, Marinomed is on the right track. According to preliminary calculations, the 2024 financial statements will close with a significant loss of around EUR 15 million due to the insolvency. After the legal completion of the restructuring proceedings, Marinomed will report a profit of around EUR 18.9 million in the first quarter of 2025 as a result of the restructuring alone. In addition, a first partial payment of EUR 5 million from the sale of the Carragelose business has already been received, so that the Company currently has sufficient liquid funds. “By focussing on our business, the successful restructuring and the associated reduction in expenses, we plan to achieve positive operating results from this year onwards. The aim now is to regain the confidence of our shareholders through operational success,” explains Andreas Grassauer, founder and CEO of Marinomed Biotech AG.
Marinomed Biotech: weekly performance: -1.06%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (27/03/2025)

Christian Drastil: Wiener Börse Plausch

D&D Research Rendezvous #13: Gunter Deuber mit Rückblick Zürs-Konferenz in Zürs von Raiffeisen und Oddo/BHF, Ausblick Märkte

Bildnachweis

Aktien auf dem Radar:Flughafen Wien, DO&CO, Porr, Pierer Mobility, RHI Magnesita, Austriacard Holdings AG, CA Immo, Polytec Group, Zumtobel, Bawag, Erste Group, FACC, Kapsch TrafficCom, OMV, Palfinger, RBI, Rosenbauer, SBO, Semperit, Wienerberger, Amag, Österreichische Post, Telekom Austria, Uniqa, VIG, MTU Aero Engines, Vonovia SE, E.ON , Symrise, Fresenius Medical Care, Airbus Group.

---